financial guidance

The firm also reaffirmed its previous guidance of 10 percent growth for fiscal 2019.

The firm also posted full-year revenue growth of approximately 3 percent to $315 million, near the top end of its guidance of $310 million to $316 million and above analysts' consensus estimate.

The company also reaffirmed its guidance for the fourth quarter, and continues to expect revenues of $46.5 million to $48.0 million and EPS of $.09 to $.11.

The company expects EPS to be between $4.02 and $4.12. On a non-GAAP basis, EPS is expected to be in the range of $4.75 and $4.85.

PacBio's shares skyrocketed 76 percent in November on the news that Illumina plans to acquire the firm for $1.2 billion in cash.

The firm saw growth of 8 percent in its life science business, 9 percent in its crosslabs group, and 9 percent in its diagnostics and genomics division in Q4.

The company said testing services revenues more than doubled during the quarter as its AlloSure kidney transplant diagnostic continued to penetrate the market.

MDx revenues increased 3 percent to $158.0 million, but excluding non-recurring royalty revenue in the prior-year period, MDx revenues increased 10 percent.

Myriad CEO Mark Capone said earnings during the quarter exceeded expectations based on strong volume growth from hereditary cancer and new products.